GNCA (Genocea Biosciences, Inc.) NASDAQ down 97.44% pre-market 23 Jan 2026: Key signals for traders
GNCA stock opened the pre-market session at $0.0001, trading down 97.44% on NASDAQ on 23 Jan 2026 on thin volume of 30,268 shares. This extreme move follows a long decline from a 52-week high of $1.45, and reflects severe liquidity stress and legacy restructuring from a Chapter 11 filing. Investors tracking Genocea Biosciences, Inc. (GNCA) should note the stock’s near-zero market cap reading and the gap between short-term averages: 50-day average price $0.00472 and 200-day average price $0.11462. We provide a concise GNCA stock analysis, risks, Meyka AI grade, and a model forecast for traders.
GNCA stock price action and volume
GNCA stock trades at $0.0001, down 97.44% pre-market with today’s volume at 30,268 versus avg volume 80,568. The one-day price change of -96.77% on short interest and low float drives outsized percentage moves. The open was $0.0007 and previous close $0.0039, showing abrupt intraday repricing tied to illiquidity rather than new clinical results.
GNCA stock fundamentals and company status
Genocea Biosciences, Inc. operates in Healthcare, Biotechnology on NASDAQ in the United States. The company filed Chapter 11 on 05 Jul 2022, a material event for valuation. Key metrics: cash per share $0.54, book value per share $0.39, current ratio 2.24, and R&D to revenue 23.78%. Net income per share TTM is -0.22, reflecting continued operating losses and limited revenue generation.
Meyka AI rates GNCA with a score out of 100 and technical view
Meyka AI rates GNCA with a score out of 100: 58.55 | Grade: C+ | Suggestion: HOLD. This grade factors in S&P 500 benchmark comparison, sector performance, financial growth, key metrics, and analyst consensus. On technicals, 50-day average $0.00472 and 200-day average $0.11462 highlight a crash below moving averages and extreme downside skew. Low liquidity and a market cap reading of 0 indicate high execution risk for traders.
GNCA stock risks and clinical catalysts
Primary risks for GNCA stock include restructuring outcomes, delisting risk, and clinical development uncertainty for GEN-009 and GEN-011 programs. Sector risk: Biotechnology volatility is elevated and healthcare peers often trade on binary trial results. Potential catalysts would be successful reorganization announcements or asset sales, but absent firm news, downside remains the more likely path given current metrics.
GNCA stock trading setup and liquidity considerations
Trading GNCA stock involves very low liquidity and wide spreads; average volume 80,568 versus today’s 30,268 implies spotty execution. Volatility metrics show multi-quarter declines: 3M -98.31%, 6M -99.09%, 1Y -99.99%. Use limit orders and small size; institutional participation is minimal. The enterprise value of -26,015,000.00 USD in data flags accounting and balance-sheet quirks to verify before trading.
GNCA stock outlook and short-term forecast
Meyka AI’s forecast model projects a conservative one-year scenario price of $0.0010, versus the current $0.0001, implying implied upside +900.00% in a recovery case. This projection compares to the 50-day average $0.00472 and is model-based. Forecasts are projections and not guarantees; downside scenarios finish near $0.0000 if restructuring eliminates equity value.
Final Thoughts
Key takeaways on GNCA stock: trading at $0.0001 pre-market on NASDAQ on 23 Jan 2026, Genocea Biosciences, Inc. shows near-zero equity pricing driven by bankruptcy-era restructuring, minimal liquidity, and large historical drawdown from a $1.45 high. Meyka AI assigns GNCA a C+ (58.55/100) grade based on benchmark and sector comparisons, financial metrics, and analyst signals. Our model projects a cautious one-year target of $0.0010 — a scenario-based projection implying +900.00% from today’s price but still well below historical averages. Traders should weigh an uncertain restructuring path, illiquid volume (today 30,268 vs avg 80,568), and clinical program risk for GEN-009 and GEN-011. This is a high-risk micro-cap situation where position sizing, limit orders, and up-to-date filings matter. Forecasts are model-based projections and not guarantees.
FAQs
What caused the GNCA stock drop pre-market?
The drop reflects extreme illiquidity, legacy Chapter 11 restructuring from July 2022, and no recent positive clinical or financing news. Low float magnifies percent moves; volume today was 30,268 versus avg 80,568.
What is the Meyka AI grade for GNCA stock?
Meyka AI rates GNCA at 58.55 out of 100, Grade C+, suggestion HOLD. The score factors in benchmark and sector comparison, financial growth, key metrics, and analyst consensus.
Does Meyka AI provide a forecast for GNCA stock?
Yes. Meyka AI’s forecast model projects a cautious one-year price of $0.0010 versus current $0.0001, implying a potential +900.00% upside in a recovery scenario. Forecasts are model-based and not guarantees.
Is GNCA stock a buy for long-term investors?
Given bankruptcy history, near-zero pricing, and clinical uncertainty, GNCA stock is high risk. Long-term buying requires conviction in restructuring outcomes and deep due diligence on filings and assets.
Disclaimer:
Stock markets involve risks. This content is for informational purposes only. Past performance does not guarantee future results. Meyka AI PTY LTD provides market analysis and data insights, not financial advice. Always conduct your own research and consider consulting a licensed financial advisor.
